Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007341
Chunk: 108

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 108
---
 |

| (5) | The selling shareholder holds (i)                                                                                                          
 warrants issued by us in prior transactions which entitle the selling shareholder to purchase an aggregate of 453,050,000 Ordinary Shares  
 (in the form of Depositary Shares), and (ii) Series J Warrants issued by us which entitle the selling                                      
 shareholder to purchase an aggregate of 212,760,000 Ordinary Shares (in the form of Depositary Shares) and Series K Warrants issued by     
 us which entitle the selling shareholder to purchase an aggregate of 212,760,000 Ordinary Shares (in the form of Depositary Shares) and    
 which we are registering hereby. The warrants are subject to a beneficial ownership limitation of 9.99%, which does not permit             
 the selling shareholder to exercise that portion of the warrants that would result in the selling shareholder and its affiliates owning,   
 after exercise, a number of our Ordinary Shares in excess of the beneficial ownership limitation. The amounts and percentages in the       
 table do not give effect to the 9.99% beneficial ownership limitation, if applicable. The principal business address of District 2 Capital 
 Fund LP is 14 Wall Street, 2nd Floor, Huntington, NY 11743.                                                                                |

| (6) | The selling                                                                                                                                   
 shareholder holds (i) warrants issued by us in prior transactions which entitle the selling shareholder                                       
 to purchase an aggregate of 103,790,000 Ordinary Shares (in the form of Depositary Shares), and (ii) Series                                   
 J Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 276,590,000 Ordinary Shares (in the form of         
 Depositary Shares) and Series K Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 276,590,000 Ordinary  
 Shares (in the form of Depositary Shares) and which we are registering hereby. The warrants are subject to a beneficial ownership limitation  
 of 4.99% or 9.99%, as applicable, which does not permit the selling shareholder to exercise that portion of the warrants that would result    
 in the selling shareholder and its affiliates owning, after exercise, a number of our Ordinary Shares in excess of the beneficial ownership   
 limitation. The amounts and percentages in the table do not give effect to the 4.99% or 9.99% beneficial ownership limitation, if applicable. 
 Richard Abbe is the managing member of Iroquois Capital Investment Group LLC